Heiner Dreismann, Former Roche Executive, Joins Nanogen Board of Directors

Oct 31, 2006, 00:00 ET from Nanogen, Inc.

    SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:  
 NGEN), developer of advanced diagnostic products, announced today that
 Heiner Dreismann, Ph.D. has been named to its Board of Directors.
 Dreismann, currently CEO of FasTraQ, Inc., has more than 20 years
 experience with Roche in the biotech and healthcare industry, most recently
 as president and CEO of Roche Molecular Systems.
     (Logo: http://www.newscom.com/cgi-bin/prnh/20050803/LAW135LOGO )
     "Heiner's extensive expertise in molecular diagnostics, particularly at
 one of the leading companies in this space, will be a huge asset to
 Nanogen," said Howard C. Birndorf, Nanogen's chairman of the board and CEO.
 "He has a strong knowledge of technology and our markets. We look forward
 to his contributions."
     "I am very enthusiastic about the future of molecular diagnostics and
 its potential to bring about higher quality health care," said Dreismann.
 "I believe that Nanogen has unique and innovative technology that can play
 a significant role in the movement toward personalized medicine."
     Dreismann has held a number of additional positions at Roche, including
 head of global business development, head of business unit PCR Europe, and
 head of business unit microbiology, all for Roche Diagnostics. He received
 a Ph.D. in microbiology/molecular biology from Westfaelische Wilhelms
 University in Muenster, Germany.
     About Nanogen, Inc.
     Nanogen's advanced technologies provide researchers, clinicians and
 physicians worldwide with improved methods and tools to predict, diagnose,
 and ultimately help treat disease. The company's products include real-time
 PCR reagents, the NanoChip(R) 400 electronic microarray platform and a line
 of rapid, point-of-care diagnostic tests. Nanogen's ten years of pioneering
 research involving nanotechnology holds the promise of miniaturization and
 continues to be supported for its potential for diagnostic and biodefense
 applications. For additional information please visit Nanogen's website at
     Nanogen Forward-Looking Statement
     This press release contains forward-looking statements that are subject
 to risks and uncertainties that could cause actual results to differ
 materially from those set forth in the forward-looking statements,
 including whether patents owned or licensed by Nanogen will be developed
 into products, whether the patents owned by Nanogen offer any protection
 against competitors with competing technologies, whether products under
 development can be successfully developed and commercialized, whether
 results reported by our customers or partners can be identically
 replicated, and other risks and uncertainties discussed under the caption
 "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or
 Form 10-Q most recently filed with the Securities and Exchange Commission.
 These forward-looking statements speak only as of the date hereof. Nanogen
 disclaims any intent or obligation to update these forward-looking

SOURCE Nanogen, Inc.